# OnCo record idea-mrd-guided-stop-cll (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-mrd-guided-stop-cll/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-mrd-guided-stop-cll" ;
  schema:name "MRD-guided treatment duration in CLL"@en ;
  schema:description "Instead of a fixed 12 or 15 months, stop each patient's therapy when their blood shows no detectable leukaemia, and restart if it returns."@en ;
  schema:url <https://onco.cc/ideas/idea-mrd-guided-stop-cll/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02910583>, <https://clinicaltrials.gov/study/NCT06073821> ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/sonrotoclax/> ;
  onco:terms <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/terms/ighv-status/> ;
  onco:trials <https://onco.cc/trials/captivate/>, <https://onco.cc/trials/celestial-tncll/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/>, <https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/>, <https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/> .